mAb Process Development and Optimization

  1. mAb Up- And Downstream Process Intensification Strategies 12/12/2024

    Discover how to reduce monoclonal antibody (mAb) manufacturing time and costs through process intensification. Learn about continuous perfusion, ultrahigh cell density banks, and more.

  2. Planning for Success: Supply Resiliency Strategies for Bench to Production 10/18/2023

    Build scalable material sourcing strategies for R&D and early phases through to commercialization and learn how to accelerate the development process and ensure the scalability of your biologics.

  3. Fast Track Your Path To Commercialization 5/21/2025

    Discover key strategies for scaling biologics from bench to pilot scale and learn how to overcome challenges in process development, including control of agitation, oxygen, CO₂, and nutrient supplementation.

  4. IND Prep Versus Clinical/Commercial Scale-Up In Novel Protein Therapeutics 9/13/2024

    In this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics, panelists share detailed considerations for scale-up of complex protein therapeutics.

  5. Process Intensification Audience Q&A 8/27/2024

    Our panelists take audience questions on process intensification lessons learned from other industries.

  6. Scalable By Design: Streamlining Cell Culture Media Manufacturing 8/15/2024

    Learn ways to help improve quality, simplify technology transfer of proprietary media formulations, and mitigate logistical challenges associated with custom media scale-up processes.

  7. Thermo Fisher Scientific Customer Experience Center Overview 5/19/2025

    Explore cutting-edge single-use technologies with hands-on training at the Customer Experience Center, which is an immersive hub for innovation, learning, and bioprocessing expertise.

  8. Scalable Production Of Lentivirus For Research To Commercial Manufacturing 10/30/2024

    Join our webinar on scaling the CTS LV-MAX System in bioreactors, covering transfection scalability, Thermo S.U.B. advantages, and DynaSpin’s efficient gene therapy integration.

  9. A Robust, Future-Ready Solution That Adapts To Your Needs 5/22/2025

    Explore a future-ready solution that features advanced automation, intuitive design, and scalable solutions to streamline your bioprocessing workflows and prepare your operations for future growth.

  10. Addressing Post-Translational Modifications In Novel Protein Therapeutics 9/13/2024

    Meinhard Hasslacher, Ph.D., Head of CMC at SOTIO Biotech, addresses an audience question on conjugation efficiencies in this segment of the Bioprocess Online Live event Early Process Considerations For Novel Protein Therapeutics. From there, we move on to an audience-led discussion on when to initially address titer, PTMS, and product quality during development of novel protein therapeutic cell lines, with Lena Tholen, Ph.D, Director of Cell Line and Bioprocess Development at FyoniBio and Neeraj Pakala, Ph.D. SVP of Product Development and Manufacturing at Vera Therapeutics weighing in.